Effects of Sacubitril/Valsartan on biomarkers of fibrosis and inflammation in patients with heart failure with reduced ejection fraction
- Standort
-
Deutsche Nationalbibliothek Frankfurt am Main
- ISSN
-
1471-2261
- Umfang
-
Online-Ressource
- Sprache
-
Englisch
- Anmerkungen
-
online resource.
- Erschienen in
-
Effects of Sacubitril/Valsartan on biomarkers of fibrosis and inflammation in patients with heart failure with reduced ejection fraction ; volume:22 ; number:1 ; day:13 ; month:5 ; year:2022 ; pages:1-8 ; date:12.2022
BMC cardiovascular disorders ; 22, Heft 1 (13.5.2022), 1-8, 12.2022
- Urheber
-
Bolla, Giovanni Battista
Fedele, Antonella
Faggiano, Andrea
Sala, Carla
Santangelo, Gloria
Carugo, Stefano
- Beteiligte Personen und Organisationen
-
SpringerLink (Online service)
- DOI
-
10.1186/s12872-022-02647-0
- URN
-
urn:nbn:de:101:1-2022071822035672665534
- Rechteinformation
-
Open Access; Der Zugriff auf das Objekt ist unbeschränkt möglich.
- Letzte Aktualisierung
-
15.08.2025, 07:21 MESZ
Datenpartner
Dieses Objekt wird bereitgestellt von:
Deutsche Nationalbibliothek. Bei Fragen zum Objekt wenden Sie sich bitte an den Datenpartner.
Deutsche Nationalbibliothek. Bei Fragen zum Objekt wenden Sie sich bitte an den Datenpartner.
Beteiligte
- Bolla, Giovanni Battista
- Fedele, Antonella
- Faggiano, Andrea
- Sala, Carla
- Santangelo, Gloria
- Carugo, Stefano
- SpringerLink (Online service)
Ähnliche Objekte (12)
Focused Treatment of Heart Failure with Reduced Ejection Fraction Using Sacubitril/Valsartan
Safety and tolerability of Sacubitril/Valsartan in heart failure patient with reduced ejection fraction
Efficacy and Dosage Pattern of Sacubitril/Valsartan in Chinese Heart Failure with Reduced Ejection Fraction Patients
Effects of sacubitril-valsartan on central and obstructive apneas in heart failure patients with reduced ejection fraction
Left atrial ejection fraction and outcomes in heart failure with preserved ejection fraction
Sacubitril/valsartan improves all-cause mortality in heart failure patients with reduced ejection fraction and chronic kidney disease
Effects of switching from sacubitril/valsartan to valsartan alone on plasma levels of natriuretic peptides and myocardial remodeling in heart failure with reduced ejection fraction
Targeting cardiac fibrosis in heart failure with preserved ejection fraction: mirage or miracle?
Dynamic trajectories of left ventricular ejection fraction in heart failure with improved ejection fraction
Real-life effectiveness of sacubitril/valsartan in older Belgians with heart failure, reduced ejection fraction and most severe symptoms
Cost-effectiveness in unstable economies: the case of sacubitril/valsartan in heart failure with reduced ejection fraction in Argentina
Hemodynamic Effects of Sacubitril/Valsartan in Patients with Reduced Left Ventricular Ejection Fraction Over 24 Months: A Retrospective Study
Focused Treatment of Heart Failure with Reduced Ejection Fraction Using Sacubitril/Valsartan
Safety and tolerability of Sacubitril/Valsartan in heart failure patient with reduced ejection fraction
Efficacy and Dosage Pattern of Sacubitril/Valsartan in Chinese Heart Failure with Reduced Ejection Fraction Patients
Effects of sacubitril-valsartan on central and obstructive apneas in heart failure patients with reduced ejection fraction
Left atrial ejection fraction and outcomes in heart failure with preserved ejection fraction
Sacubitril/valsartan improves all-cause mortality in heart failure patients with reduced ejection fraction and chronic kidney disease
Effects of switching from sacubitril/valsartan to valsartan alone on plasma levels of natriuretic peptides and myocardial remodeling in heart failure with reduced ejection fraction
Targeting cardiac fibrosis in heart failure with preserved ejection fraction: mirage or miracle?
Dynamic trajectories of left ventricular ejection fraction in heart failure with improved ejection fraction
Real-life effectiveness of sacubitril/valsartan in older Belgians with heart failure, reduced ejection fraction and most severe symptoms
Cost-effectiveness in unstable economies: the case of sacubitril/valsartan in heart failure with reduced ejection fraction in Argentina
Hemodynamic Effects of Sacubitril/Valsartan in Patients with Reduced Left Ventricular Ejection Fraction Over 24 Months: A Retrospective Study
Focused Treatment of Heart Failure with Reduced Ejection Fraction Using Sacubitril/Valsartan
Safety and tolerability of Sacubitril/Valsartan in heart failure patient with reduced ejection fraction
Efficacy and Dosage Pattern of Sacubitril/Valsartan in Chinese Heart Failure with Reduced Ejection Fraction Patients
Effects of sacubitril-valsartan on central and obstructive apneas in heart failure patients with reduced ejection fraction
Left atrial ejection fraction and outcomes in heart failure with preserved ejection fraction
Sacubitril/valsartan improves all-cause mortality in heart failure patients with reduced ejection fraction and chronic kidney disease
Effects of switching from sacubitril/valsartan to valsartan alone on plasma levels of natriuretic peptides and myocardial remodeling in heart failure with reduced ejection fraction
Targeting cardiac fibrosis in heart failure with preserved ejection fraction: mirage or miracle?
Dynamic trajectories of left ventricular ejection fraction in heart failure with improved ejection fraction
Real-life effectiveness of sacubitril/valsartan in older Belgians with heart failure, reduced ejection fraction and most severe symptoms
Cost-effectiveness in unstable economies: the case of sacubitril/valsartan in heart failure with reduced ejection fraction in Argentina